September 21, 2004

PROCYTE EXPANDS ASIA-PACIFIC DISTRIBUTION

Redmond, Wash.—September 21, 2004—ProCyte Corporation (OTCBB: PRCY.OB), today announced the expansion of its international distribution network for its skin care and hair care products with the addition of five companies in the Asia-Pacific market over the past several months. The new distributors are located in Taiwan, Hong Kong, Korea, Malaysia and Australia. This is a significant expansion in international coverage for the ProCyte medical, spa and consumer products in the dynamic $11.2 billion, growing markets for anti-aging and skin care products. In 2001, the Asia-Pacific skin care markets accounted for over 37% of all skin care sales worldwide. Skin whitening products are highly desirable in Asian countries and account for a major portion of skin care sales. ProCyte’s GHK copper peptide has been shown in clinical studies to brighten the skin and even out skin tone without irritation.

Additionally, ProCyte’s top-selling Ti-Silc^® SPF 45 product currently holds certification from the Australian Photobiology Testing Facility for broad spectrum sun protection. According to Global Cosmetic Industry magazine, the sun care market in the Asia Pacific market in 2002 was $324.4 million with a growth rate of 8% and the Australian market was $43.5 million with a growth rate of 13.3%.

“We will begin to generate revenue from these distributors in the third quarter and expect volumes to increase over the next several quarters as product registrations are completed in each country and promotional programs are implemented,” said Jack Clifford, President and CEO. “These distributors are in addition to new distribution we added recently in Latin America, which is growing very nicely.”

ProCyte Corporation develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. The Company sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including its long-term worldwide license agreement with Neutrogena^®, a Johnson & Johnson company. ProCyte brands include Neova^®, VitalCopper^™, Simple Solutions^® and AquaSanté^® Skin Care products; Complex Cu₃^® Post-Procedure Skin Care; GraftCyte^® Hair Transplant Care; and Tricomin^® Advanced Care for Thinning Hair. The Company also has the exclusive distribution rights for Cutanix Corporation’s Quadrinone^® technology in the U.S., Canada and Puerto Rico. Additional information is available by visiting the Company’s website at www.procyte.com.

###

This release may contain forward-looking statements relating to the research, development, commercialization, production, marketing and distribution of the Company's products and future operating results, which are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words “believe,” “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect the Company’s actual results include its ability to develop, commercialize and produce new products; the market acceptance of existing and potential future products; the availability, cost and timely delivery of materials and services from and performance of third-party suppliers, manufacturers, distributors, licensees and other collaborative partners; the satisfaction of regulatory requirements, and the receipt, timing, terms and conditions of required regulatory approvals. Reference is made to the Company’s Annual Report on Form 10-K for the year ended December 31, 2003 and its latest quarterly report on Form 10Q filed with the Securities and Exchange Commission for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.